In an open-label extension study, consistent and sustained LDL-c reduction was seen upon changing the dose of alirocumab based on LDL-c level, allowing for an individualized approach.

The contemporary CHAMP-HF registry of HFrEF patients revealed that <10% of patients eligible for ACEi/ARB/ARNI and BB therapy received target doses, also when SBP was >110 mmHg.

A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.

Consuming a diet with red meat as the main protein source for 4 weeks results in substantial increases in gut-microbiota-produced TMAO levels, as compared with isocaloric white meat and non-meat diets.

Bariatric surgery in obese subjects with hypertension resulted in reduced need for antihypertensive medication with similar ABPM profile and nondipping status, and reduced BP variability and lower number of patients with resistant hypertension compared to medical therapy.

In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.

This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.

The long-term CAROLINA trial met its primary endpoint, defined as non-inferiority of linagliptin vs. glimepiride in time to first occurrence of 3P-MACE in adults with T2DM .

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In ANNEXA-4, andexanet alfa infusion resulted in rapid reversal of anti-factor Xa activity and excellent or good hemostatic efficacy at 12 hours was achieved in 82% of patients with major bleeding.

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

In the ORBIT-AF multicenter cohort study, AF patients with cognitive impairment or frailty showed higher stroke risk and mortality, but OACs were underprescribed. The conditions did not affect OAC treatment effect.